Luxembourg Sound infrastructure, a prime location in the heart of Europe, government support, and an unwavering focus on quality are all helping make the tiny principality of Luxembourg a serious player in global healthcare logistics. “Some high ranked senior logistics executives from pharma companies have commented that [the Luxair Cargo Healthcare &…
London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…
France Shedding light on the unique business model of French pharma’s most successful mid-cap. Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for…
Slovakia Pharma companies in Slovakia are managing to circumvent the problems inherent in the size of the local market by focusing on the country’s advantages in market access and regional leadership, as well as through joining together with affiliates in neighboring Czech Republic. “Slovakia is a developed and established EUR 1.25…
Mexico Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare. Here, representatives of government, associations, social security institutions, and private companies impart their expertise on how best to navigate these…
Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…
Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…
Philippines Key executives and industry leaders convened in September in Manila to discuss the dynamic and evolving healthcare industry in the Philippines, and how QuintilesIMS’ expanding technological portfolio of services will best allow companies to drive their momentum in the future. Technology is also impacting other sectors in the country, including…
France Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this field, with a number of companies, institutes and hospitals pioneering new forms of treatment and adapting policy to fit the…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it a compelling choice. “Switzerland was actually the obvious choice for kick-starting our international operations because the local ecosystem is so…
Czech Republic One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the regional leaders in pharmaceuticals, healthcare and life sciences. In the Czech Republic we have the right balance between sophisticated…
See our Cookie Privacy Policy Here
